At-Home Genetic Testing Goes Beyond Just DNA
The Dave and Dave Show looks at 23andMe’s DNA test-taking kit and its recent approval by the FDA to scan for certain breast cancer genes. We examine the possibilities and limitations, where the market is headed, and what it means for the biotech industry and its business advisors.
Dave Plaskow: Hello and welcome to EisnerAmper’s technology podcast series.
With more than 500 technology clients, we’re always interested in the latest industry trends and developments as well as any related business and accounting opportunities and challenges. I’m your host Dave Plaskow and with us today is Dave Katz, Senior Manager in EisnerAmper’s Technology and Life Sciences Practice. It’s another episode of the Dave and Dave show. Today’s episode is on a mail-in DNA kit that can screen for breast cancer genes. Hi Dave.
Dave Katz: Hi Dave, how are you?
DP: Good. So last time we spoke we talked about the Apple Watch accessory that can act as an EKG. So now the 23andMe, that mail-in DNA test-taking-kit company (there’s a few of them out there) but the kit can actually tell customers about three mutations in the breast cancer genes BRCA1 and BRCA2. Now these are a couple of consumer-based products that the FDA has really had a hand in repositioning.
DK: Correct. The trend has been increased access to health care information. 23andMe received FDA authorization on carrier test for Bloom Syndrome in 2015 and risk report for several conditions such as Parkinson’s and Alzheimer’s in 2017. Industry people have called it the continued march of the democratization of health care.
DP:What’s the down side here?
DK: So 23andMe only tests for three mutations in BRCA1 and one in BRCA2. These mutations are among the most common and best studied but they still account for only a fraction of hereditary breast cancers in the U. S. There are more 1,000 known BRCA mutations, some of which are linked to increased cancer risk, some of which aren’t, others whose risk is unknown. So the test doesn’t cast a very wide net, and it’s certainly not a replacement for regular visits to your physician.
DP:What are we talking about here in dollars and cents?
DK: A variety of companies offer kits that cost anywhere from $99 to $199 each. The global consumer genetic testing market was $70 million in 2015 and is expected to be $340 million by 2022.
DP:That’s almost a fivefold increase. So how might something like this, what we talked about as far as the increased access to health care information, how can this impact the life science and biotech sector as well as impact people like you who provide business consulting services?
DK: Anytime a company can move through FDA approval, it’s good for the industry. It challenges other companies; it shows the willingness of the FDA to accept newer methods of testing. So we should see continued investing and funding in the industry, and with that comes the need for qualified business partners to be there every step of the way.
DP:Great. Dave, thanks for your expertise here.
DK: Thanks Dave.
DP:And thank you for listening to another episode of the Dave and Dave show, as part of the EisnerAmper podcast series. Visit EisnerAmper.com for more information on this, and a host of other topics. And join us for our next EisnerAmper podcast when we get down to business.
Cryptocurrency still has the reputation for significant price swings. In this episode of the Dave & Dave Show, we look at a new contender—with some big backers—that’s tied to the U.S. dollar to help temper that volatility.
The Dave & Dave Show takes a look at a tech startup, Aerobotics, that is using drones to help farmers in South Africa.
In this episode of the Dave and Dave show, we look at a 3D-printed housing community for needy families in El Salvador, the goals are, some of the attached business issues, and how this could be a technological game-changer for affordable housing.
The “Dave & Dave Show” examines a few interesting things Amazon is up to on its march toward global e-tail domination, such as its choosing a city for its new headquarters, its foray into health care, Amazon Go and more.
This episode of “The Dave & Dave Show” covers a unique, FDA-approved EKG device for the Apple Watch. We’ll discuss the science and the business behind this promising new technology, as well as how the market for smart watches is doing.
In this final Dave & Dave podcast of 2017, we examine the technology headlines that caught our attention toward the end of the year, including net neutrality, the data hack at Uber, some misbehaving drones and what might be on the menu for 2018.
In this episode of “The Dave & Dave Show,” we talk about the debut of the world’s first ETF powered by artificial intelligence (AI). We discuss the technology behind it, if it impacts a fund’s expense ratio and, most importantly, how it’s performing.
The iPhone X has put a renewed spotlight on facial recognition technology. Dave Katz gives us a history on this type of technology, some of the privacy and security issues, what the market looks like and which companies are leading the charge.
In this episode of 'The Dave & Dave Show,' we discuss the technology and financing issues related to the possible return of supersonic air travel. What does today’s market look like for supersonic air travel and can start-ups navigate the many challenges?
Will the robot vacuum collect customer household data and offer it to technology companies to enhance internet of things devices? Here is what information is being collected, potential data privacy and security issues, and iRobot’s response to consumer concerns.
In this episode of the Dave & Dave Show, EisnerAmper Senior Audit Manager Dave Katz tells us about electric car company Tesla receiving a significant investment from Chinese technology giant Tencent.
Dave Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, discusses recent mergers and acquisitions in e-commerce including Amazon's recent acquisition of Souq, a Dubai based e-commerce company.
With tech jobs are estimated to double over the next decade, this episode of the Dave and Dave show, as part of EisnerAmper’s Technology Podcast, discusses the market for tech talent and what the forecast for tech employment looks like.
Dave Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, and Richard Colloca, Partner-in-Charge of EisnerAmper’s Food and Beverage Group, discuss Amazon’s plan to use 'Just Walk Out Technology.'
David Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, gives a “state of the union” on self-driving cars, an overview of Uber’s unique experiment in Pittsburgh, and a glimpse of what we can expect in the marketplace.
In this episode of the Dave & Dave show, we learn about the real estate shortage for biotech hubs, the challenges of obtaining new space, how early-stage companies are coping, and what’s on the drawing board to help alleviate the shortage.
In this episode of the Dave & Dave Show, Dave Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, tells us about this space-age technology that could revolutionize personal travel and commercial traffic.
David Katz, Senior Audit Manager in EisnerAmper's Technology and Life Sciences Practice, discusses the commercial drone market, including potential markets, barriers to entry and where capital investment is headed.
David Katz, Senior Audit Manager in EisnerAmper's Technology and Life Sciences Practice, discusses some of the financial aspects of virtual reality, such as investment, valuation, revenue recognition and more.